Sanofi-Aventis factory audit super network guidance latest passed

Sanofi-Aventis Group English: Sanofi-Aventis
The so-called Sanofi-Aventis factory inspection is the factory inspection of the Sanofi-Aventis Group, which is an audit and evaluation of the Sanofi-Aventis Group on its suppliers or subcontractors.
Are you fully prepared before the Sanofi-Aventis Group factory inspection? It is necessary for you to not only understand the relevant knowledge of the Sanofi-Aventis Group factory inspection standards, but also understand how important it is to choose a reliable factory inspection consulting company for guidance (Shanghai Chaowang Sanofi-Aventis Group factory inspection guidance brand, your best choice)

Business in China
Aventis' business in China includes Aventis Pharmaceuticals, Aventis Pasteur (vaccines), and Aventis Belin (plasma protein).
Aventis Pharmaceuticals (China) is headquartered in Shanghai, with offices in Beijing, Guangzhou, Hangzhou and other provinces and cities. In 1995, it signed a joint venture agreement with its partner China National Pharmaceutical Industry Corporation to establish Beijing Aventis Pharmaceuticals Co., Ltd. The company is located in Beijing Economic and Technological Development Zone, with a production capacity of more than 1.5 million units.
Aventis Pharmaceuticals (China) focuses on therapeutic areas such as cardiovascular, oncology, diabetes, central nervous system, anti-infection and digestive system.
Beijing Aventis Pharmaceuticals Co., Ltd. is a joint venture factory that meets international standards and has obtained the GMP certification from the State Food and Drug Administration.
The birth of the Sanofi-Aventis Group:
With the successful acquisition of Aventis by Sanofi-Synthelabo, Sanofi-Aventis Group was born on August 20, 2004.
Both companies have operations in China.
Currently, Sanofi-Aventis ranks seventh in China, with a market share of 1.7%. Sanofi-Aventis has been working hard to create an atmosphere of harmony, openness, fair competition and mutual respect.
In 2005, Sanofi-Aventis' pro forma consolidated net sales[1] reached 27.311 billion euros, a comparable growth of 9.3%. It is one of the world's leading pharmaceutical companies, with operations in more than 100 countries and 100,000 employees. Its headquarters is in Paris, France. Sanofi-Aventis ranks fifth among the top 20 pharmaceutical companies in China and is headquartered in Shanghai.

Seven major therapeutic areas
Sanofi-Aventis' products focus on seven major therapeutic areas:
* Cardiovascular disease
* Blood clots
* Tumor
* Central nervous system diseases
* Metabolic syndrome
* Internal medicine medication
* vaccine